Back to discover

Protein / target

Spermidine synthase

Encoded bySRMP19623Homo sapiensSwiss-Prot
UniProt: P19623Ensembl: ENSG00000116649HGNC: HGNC:11296NCBI Gene: 6723
Small-molecule tractable
Druggability
Structure with Ligand
1
Research papers

Protein at a glance

Biological role

Protein homodimerization

Strongest disease association

Obesity disorder

Via encoding gene SRM · Genetic evidence · score 0.10

Research activity

Emerging research

1 papers · latest 1986

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

Catalyzes the production of spermidine from putrescine and decarboxylated S-adenosylmethionine (dcSAM).

View complete UniProt function annotation

Catalyzes the production of spermidine from putrescine and decarboxylated S-adenosylmethionine (dcSAM). Has a strong preference for putrescine as substrate, and has very low activity towards 1,3-diaminopropane. Has extremely low activity towards spermidine

Domains and Gene Ontology detail (8)

Domains & features

PABS

Gene Ontology

  • Ccytosol
  • Fidentical protein binding
  • Fprotein homodimerization activity
  • Fspermidine synthase activity
  • Ppolyamine metabolic process
  • Pspermidine biosynthetic process
  • Pspermine biosynthetic process

302 aa · 34 kDa

Translational evidence

Open Targets 26

Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.

Strongest disease associations · via encoding gene SRM

Gene-level evidence surfaced through the gene SRMthat encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.

Obesity disorder
0.11Preliminary

Genetic evidence dominant · Open Targets 0.06

Diabetic Neuropathies
0.10Preliminary

Genetic evidence dominant · Open Targets 0.06

Urinary Bladder Neoplasms
0.04Preliminary

Literature evidence dominant · Open Targets 0.03 · no direct causal or clinical evidence

Urinary bladder carcinoma
0.04Preliminary

Literature evidence dominant · Open Targets 0.03 · no direct causal or clinical evidence

Tuberculosis
0.04Preliminary

Literature evidence dominant · Open Targets 0.03 · no direct causal or clinical evidence

View evidence synthesis (5)
Obesity disorderPreliminary
0.11
agreement 0.00–0.24
Genetic96%Literature4%

Open Targets aggregate 0.06 · 2 independent evidence families

Diabetic NeuropathiesPreliminary
0.10
agreement 0.00–0.22
Genetic100%

Open Targets aggregate 0.06 · 1 independent evidence family

Urinary Bladder NeoplasmsPreliminary
0.04
agreement 0.00–0.32
Literature100%

Open Targets aggregate 0.03 · 1 independent evidence family · no direct causal or clinical evidence

Urinary bladder carcinomaPreliminary
0.04
agreement 0.00–0.32
Literature100%

Open Targets aggregate 0.03 · 1 independent evidence family · no direct causal or clinical evidence

TuberculosisPreliminary
0.04
agreement 0.00–0.31
Literature100%

Open Targets aggregate 0.03 · 1 independent evidence family · no direct causal or clinical evidence

The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.

Show all associations
Obesity disorder0.06
Diabetic Neuropathies0.06
Urinary Bladder Neoplasms0.03
Urinary bladder carcinoma0.03
Tuberculosis0.03
Carcinoma, Hepatocellular0.03
Prostatic Neoplasms0.03
Familial prostate cancer0.03
Prostate carcinoma0.03

Tractability

Small molecules — Emerging

Feasibility evidence (structure with ligand and high-quality pocket) — no clinical-stage drug of this modality recorded.

Protein degraders — Emerging

Feasibility evidence (database ubiquitination and half-life data) — no clinical-stage drug of this modality recorded.

View underlying tractability evidence (6)
SM · Structure with LigandSM · High-Quality PocketSM · Druggable FamilyPR · Database UbiquitinationPR · Half-life DataPR · Small Molecule Binder

Raw Open Targets tractability assessment buckets, by modality.

Research activity

1 papers · to 1986

Papers linked directly to this protein. This is the protein's own literature — descriptor-derived papers are kept separate below.

Most cited

Recent advances in the biochemistry of polyamines in eukaryotes.1,096 cites

Pegg AE · The Biochemical journal · 1986

Recent

Recent advances in the biochemistry of polyamines in eukaryotes.

Pegg AE · The Biochemical journal · 1986

Europe PMC papers linked directly to this protein.